<DOC>
	<DOCNO>NCT00829205</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer cell growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer cell-killing substance . Drugs use chemotherapy , ifosfamide , carboplatin , etoposide , work different way stop growth cancer cell , either kill cell stop divide . Se-methyl-seleno-l-cysteine may help reduce side effect chemotherapy . PURPOSE : This phase I/II trial study side effect best dose Se-methyl-seleno-l-cysteine give together rituximab , ifosfamide , carboplatin , etoposide see well work treat patient diffuse large B-cell lymphoma relapse responded treatment .</brief_summary>
	<brief_title>Se-Methyl-Seleno-L-Cysteine , Rituximab , Ifosfamide , Carboplatin , Etoposide Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed Not Responded Treatment</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess dose-limiting toxicity maximum-tolerated dose ( MTD ) Se-methyl-seleno-L-cysteine ( MSC ) ( achieve trough serum selenium [ Se ] concentration &gt; 20 μmol/L ) prior combination rituximab , ifosfamide , carboplatin , etoposide ( R-ICE ) patient relapse refractory diffuse large B-cell lymphoma . ( Phase I ) - To determine overall response rate R-ICE give addition MSC MTD patient . ( Phase II ) Secondary - To determine toxicity R-ICE use combination MSC patient . - To determine effect MSC dose serum intracellular Se Se species patient . - To determine pharmacokinetics MSC single multiple daily dose patient . - To investigate effect MSC dose Se-dependent process ( e.g. , NFκB activity AKT ) . OUTLINE : This multicenter , phase I , dose-escalation study Se-methyl-seleno-L-cysteine ( MSC ) follow phase II study . Patients receive rituximab IV day 1 , carboplatin IV day 2 , ifosfamide IV etoposide IV day 2-4 ( R-ICE ) , filgrastim ( G-CSF ) subcutaneously day 6-13 . Patients also receive oral MSC twice daily day -7 0 daily course 1-2 . Treatment R-ICE G-CSF repeat every 21 day 3 course absence disease progression unacceptable toxicity . Blood sample collect periodically analyze pharmacokinetics protein marker . After completion study treatment , patient follow monthly 3 month . This study peer review funded endorsed cancer research UK .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Selenomethylselenocysteine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm , CD20+ , diffuse large Bcell lymphoma ( DLBCL ) accord WHO lymphoma classification Histological transformation previously know indolent lymphoma allow Biopsyproven DLBCL arise indolent lymphoma diagnose previously allow Disease first relapse complete remission , partial response ( PR ) , less PR firstline treatment No primary CNS lymphoma PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 3 month Serum creatinine &lt; 150 μmol/L Serum bilirubin &lt; 35 μmol/L Transaminases &lt; 2.5 time upper limit normal ( unless attribute lymphoma ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No contraindication drug contain immunochemotherapy regimen No malignancy within past 2 year , except basal cell squamous cell carcinoma skin carcinoma situ cervix No serious active disease , opinion investigator , would preclude patient conventional chemotherapy No HIV positivity No medical psychiatric condition compromise patient 's ability give inform consent PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
</DOC>